Last reviewed 2026-04-23 · How we verify

induction chemotherapy (mDCF)

Federation Francophone de Cancerologie Digestive · Phase 3 active Small molecule

induction chemotherapy (mDCF) is a Combination chemotherapy regimen Small molecule drug developed by Federation Francophone de Cancerologie Digestive. It is currently in Phase 3 development for Metastatic or locally advanced gastric cancer (induction therapy), Esophageal cancer (induction therapy).

mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers.

mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers. Used for Metastatic or locally advanced gastric cancer (induction therapy), Esophageal cancer (induction therapy).

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	induction chemotherapy (mDCF)
Sponsor	Federation Francophone de Cancerologie Digestive
Drug class	Combination chemotherapy regimen
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

mDCF (modified docetaxel, cisplatin, and fluorouracil) is a triplet chemotherapy combination where docetaxel acts as a microtubule stabilizer, cisplatin causes DNA cross-linking, and fluorouracil inhibits thymidylate synthase. Together, these agents target rapidly dividing cancer cells through multiple mechanisms to achieve cytotoxic effects in advanced digestive tract malignancies.

Approved indications

Metastatic or locally advanced gastric cancer (induction therapy)
Esophageal cancer (induction therapy)

Common side effects

Neutropenia
Anemia
Thrombocytopenia
Nausea and vomiting
Mucositis
Diarrhea
Peripheral neuropathy

Key clinical trials

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

induction chemotherapy (mDCF) CI brief — competitive landscape report
induction chemotherapy (mDCF) updates RSS · CI watch RSS
Federation Francophone de Cancerologie Digestive portfolio CI

Frequently asked questions about induction chemotherapy (mDCF)

What is induction chemotherapy (mDCF)?

induction chemotherapy (mDCF) is a Combination chemotherapy regimen drug developed by Federation Francophone de Cancerologie Digestive, indicated for Metastatic or locally advanced gastric cancer (induction therapy), Esophageal cancer (induction therapy).

How does induction chemotherapy (mDCF) work?

mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers.

What is induction chemotherapy (mDCF) used for?

induction chemotherapy (mDCF) is indicated for Metastatic or locally advanced gastric cancer (induction therapy), Esophageal cancer (induction therapy).

Who makes induction chemotherapy (mDCF)?

induction chemotherapy (mDCF) is developed by Federation Francophone de Cancerologie Digestive (see full Federation Francophone de Cancerologie Digestive pipeline at /company/federation-francophone-de-cancerologie-digestive).

What drug class is induction chemotherapy (mDCF) in?

induction chemotherapy (mDCF) belongs to the Combination chemotherapy regimen class. See all Combination chemotherapy regimen drugs at /class/combination-chemotherapy-regimen.

What development phase is induction chemotherapy (mDCF) in?

induction chemotherapy (mDCF) is in Phase 3.

What are the side effects of induction chemotherapy (mDCF)?

Common side effects of induction chemotherapy (mDCF) include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Mucositis, Diarrhea.

Drug class: All Combination chemotherapy regimen drugs
Manufacturer: Federation Francophone de Cancerologie Digestive — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Metastatic or locally advanced gastric cancer (induction therapy)
Indication: Drugs for Esophageal cancer (induction therapy)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing